- University College, Dublin, Ireland - MD
- Medical College of Wisconsin, Milwaukee, Wisconsin - Residency in Internal
- Northwestern University - Residency in Internal Medicine
- Mater Hospital, Dublin, Ireland - Fellowship in Oncology
- Northwestern University - Fellowship in Hematology/Oncology
the Department of Medicine. As Associate Director, Clinical Research at University of Wisconsin Carbone Cancer Center (UWCCC), Dr. O’Regan oversees all aspects of UWCCC’s clinical research. Dr. O’Regan is an internationally recognized breast cancer physician and researcher and is ranked by Newsweek/Castle Connolly Medical as one of the top oncologists in the nation. She is the Chief Scientific officer (CSO) of the Big Ten Cancer Research Consortium (Big Ten CRC) where she guides the research and scientific mission of the consortium and works closely with the Steering Committee and Clinical Trial Working Groups to identify and support the most promising clinical trials to be conducted through the consortium. Dr. O’Regan is Vice-Chair of the Wisconsin Association of Hematology and Oncology, President, Wisconsin Association of Hematology and Oncology (WAHO) Board of Directors, and serves on the Executive Committee for the National Comprehensive Cancer Network (NCCN).
Dr. O’Regan is a member of the American Association for Cancer Research, NRG Oncology, and the American Society of Clinical oncology, among other professional memberships. She has active funding and portfolio as PI of several breast specific clinical trials. Dr. O’Regan previously was the Louisa and Rand Glenn Family Chair in Breast Cancer Research at Emory University, in addition to medical director at Glenn Family Breast Center of Emory University, and director of the Breast Cancer Translational Research Program at the Winship Cancer Institute.
Dr. O’Regan’s clinical interests include breast cancer and medical oncology.
View Dr. Ruth O’Regan’s Publications on NCBI My Bibliography
Dr. O’Regan’s research program broadly focuses on identifying mechanisms of resistance to breast-cancer therapies and development of new therapies. She has active funding and portfolio as PI of several breast specific clinical trials. Her current research examines the development of novel therapeutic approaches to treat resistant breast cancers, including triple negative breast cancer.